A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis

New England Journal of Medicine

Volumn 338, Issue 7, 1998, Pages 409-415

  Decousus, Hervé ^a,h   Leizorovicz, Alain ^b   Parent, Florence ^c   Page, Yves ^a   Tardy, Bernard ^a   Girard, Philippe ^d   Laporte, Silvy ^a   Faivre, René ^e   Charbonnier, Bernard ^f   Barral, Fabrice Guy ^a   Huet, Yann ^g   Simonneau, Gérald ^c  

^a SERVICE DE NEUROLOGIE   (France)

^b Clinical Pharmacology Unit   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e Clinique Saint Vincent   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g SANOFI   (France)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VENA CAVA FILTER;

AGED; ANTICOAGULANTS; COMBINED MODALITY THERAPY; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; PULMONARY EMBOLISM; RECURRENCE; SURVIVAL ANALYSIS; THROMBOPHLEBITIS; TREATMENT OUTCOME; VENA CAVA FILTERS;

EID: 6844254566     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802123380701     Document Type: Article

References (30)

1. Phlegmatia alba dolens. In: Trousseau A. Clinique médicale de l'Hôtel-Dieu de Paris. 3rd ed. Vol. 3. Paris: J.B. Baillière, 1868:652-95.
2. Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena cava filter. Surgery 1988;104:706-12.
3. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:Suppl:335S-351S.
4. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs 1996;52:Suppl 7:30-7.
5. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Intern Med 1992;152:1985-94.
6. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for Healthcare professionals. Circulation 1996;93: 2212-45.
7. Page Y, Decousus H, Tardy B, et al. Criteria for prophylactic caval interruption in venous thromboembolism: a survey. Am Rev Respir Dis 1993;147:Suppl:A1001. abstract.
8. Walsh DB, Birkmeyer ID, Barrett JA, Kniffin WB, Cronenwett JL, Baron JA. Use of interior vena cava filters in the Medicare population. Ann Vase Surg 1995;9:483-7.
9. Greenfield LJ, Proctor MC. Current indications for caval interruption: should they be liberalized in view of improving technology? Semin Vasc Surg 1996;9:50-8.
10. Magnant JG, Walsh DB, Juravsky LI, Cronenwett JL. Current use of inferior vena cava filters. J Vase Surg 1992;16:701-6.
11. Alexander JJ, Gewertz BL, Lu C-T, Zarins CK. New criteria for placement of a prophylactic vena cava filter. Surg Gynecol Obstet 1986;163: 405-9.
12. Kinasewitz GT. Thrombophlebitis and pulmonary embolism in the elderly patient. Clin Chest Med 1993;14:523-36.
13. Pomper SR, Lutchman G. The role of intracaval filters in patients with COPD and DVT. Angiology 1991;42:85-9.
14. Fink JA, Jones BT. The Greenfield filter as the primary means of therapy in venous thromboembolic disease. Surg Gynecol Obstet 1991;172: 253-6.
15. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991;109:12-5.
16. Golueke PJ, Garrett WV, Thompson JE, Smith BL, Talkington CM. Interruption of the vena cava by means of the Greenfield filter: expanding the indications. Surgery 1988;103:111-7.
17. Berry RE, George JE, Shaver WA. Free-floating deep venous thrombosis: a retrospective analysis. Ann Surg 1990;211:719-23.
18. Dorfman GS. Evaluating the roles and function of vena caval filters: will data be available before or after these devices are removed from the market? Radiology 1992;185:15-7.
19. Goldhabcr SZ. A free-floating approach to filters. Arch Intern Med 1997;157:264-5.
20. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (HOPED). JAMA 1990;263:2753-9.
21. Moser KM, Longo AM, Ashburn WL, Guisan M. Spurious scintiphotographic recurrence of pulmonary emboli. Am J Med 1973;55:434-43.
22. Girard P, Mathieu M, Simonneau G, et al. Recurrence of pulmonary embolism during anticoagulant treatment: a prospective study. Thorax 1987;42:481-6.
23. Brandjes DPM, Heijboer H, Büller HR, de RiJk M, Jagt H, ten Cate JW. Aeenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327: 1485-9.
24. Prandoni P, Cogo A, Bernards E, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993;88: 1730-5.
25. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
26. Hull RD, Raskob GE, Roscnbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Mcd 1990;322:1260-4.
27. Byar DP, Piantadosi S. Factorial designs for randomized clinical trials. Cancer Treat Rep 1985;69:1055-63.
28. Tardy B, Mismetti P, Page Y, et al. Symptomatic interior vena cava filter thrombosis: clinical study of 30 consecutive cases. Eur Respir J 1996;9: 2012-6.
29. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-62.
30. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.